Precision Neuroscience Raises $250 Million to Advance Its Brain-Computer Interface Through FDA Review

Precision Neuroscience has raised $250 million in an oversubscribed Series D financing round, the brain-computer interface company announced on 29 September. The funding brings total capital raised to $430 million and will support continued clinical trials, FDA regulatory review and preparations for eventual commercialisation.

The New York-based company develops a cortical electrode array called the Layer 7, which sits on the brain's surface rather than penetrating it. The less invasive approach is designed to reduce the risks of tissue damage and signal degradation that can affect implanted electrodes over time. Precision Neuroscience was co-founded by Benjamin Rapoport, who was previously a founding member of Neuralink.

The BCI field is accelerating. Paradromics separately demonstrated in September 2026 that its Connexus BCI could help restore real-time speech to a woman with progressive motor neuron disease — the first participant in a 10-person feasibility study. Meanwhile, researchers at a separate institution published work on a needle-thin 'mAxialtrode' that combines recording, stimulation and drug delivery in a single fibre.

The $250 million raise is one of the larger rounds in the BCI space and reflects investor confidence in the technology's near-term clinical viability. However, converting promising clinical results into products that regulators approve and that hospitals adopt at scale remains a multi-year challenge, with chronic biocompatibility and long-term signal stability still active areas of research.